Pure Global

A Clinical Trial to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules - Trial NCT06306872

Access comprehensive clinical trial information for NCT06306872 through Pure Global AI's free database. This Phase 1 trial is sponsored by Abbisko Therapeutics Co, Ltd and is currently Recruiting. The study focuses on Healthy Subjects. Target enrollment is 73 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06306872
Phase 1
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06306872
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Clinical Trial to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules
A Single-center, Open-label, Multi-period Study to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules and the Effects of Low-fat Diet, High-fat Diet and Omeprazole Magnesium Enteric-coated Tablets on the Pharmacokinetic Profile of New ABSK-011 Capsules in Healthy Subjects

Study Focus

Healthy Subjects

Sequence A ABSK-011

Interventional

drug

Sponsor & Location

Abbisko Therapeutics Co, Ltd

Wuxi, China

Timeline & Enrollment

Phase 1

Feb 23, 2024

Dec 31, 2024

73 participants

Primary Outcome

Cmax,AUC,tmax

Summary

The main objective of which is to evaluate the relative bioavailability and PK
 characteristics of new and old ABSK-011 capsules in a single oral dose

ICD-10 Classifications

Occupational health examination
Seeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmful
Routine child health examination
Examination and observation for other reasons

Data Source

ClinicalTrials.gov

NCT06306872

Non-Device Trial